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Abstract: Charcot-Marie-Tooth disease (CMT) is a heritable neurodegenerative disease that displays
great genetic heterogeneity. The genes and mutations that underlie this heterogeneity have been
extensively characterized by molecular genetics. However, the molecular pathogenesis of the vast
majority of CMT subtypes remains terra incognita. Any attempts to perform experimental therapy
for CMT disease are limited by a lack of understanding of the pathogenesis at a molecular level.
In this study, we aim to identify the molecular pathways that are disturbed by mutations in the
gene encoding GDAP1 using both yeast and human cell, based models of CMT-GDAP1 disease. We
found that some mutations in GDAP1 led to a reduced expression of the GDAP1 protein and resulted
in a selective disruption of the Golgi apparatus. These structural alterations are accompanied by
functional disturbances within the Golgi. We screened over 1500 drugs that are available on the
market using our yeast-based CMT-GDAP1 model. Drugs were identified that had both positive and
negative effects on cell phenotypes. To the best of our knowledge, this study is the first report of the
Golgi apparatus playing a role in the pathology of CMT disorders. The drugs we identified, using
our yeast-based CMT-GDAP1 model, may be further used in translational research.
Keywords: Charcot-Marie-Tooth disease; GDAP1 gene; Golgi apparatus; inflammation; molecular
mechanisms; neuropathy; therapy; yeast-based model organism
1. Introduction
Charcot-Marie-Tooth disease (CMT) is a heritable neurodegenerative disease that dis-
plays extreme genetic heterogeneity. Over the last three decades, more than 100 genes have
been identified as being involved in CMT disease. Despite these advances on the molecular
genetics front, the molecular pathogenesis of different CMT subtypes remains unexplored.
This lack of understanding at the molecular level has contributed to a lack of effective
treatments. CMT disease, resulting from mutations within the gene encoding Ganglioside
Induced Differentiation Associated Protein 1 (GDAP1; referred to as CMT-GDAP1), espe-
cially from recessive ones, is characterized by a relatively severe clinical outcome. Usually,
symptoms first appear during early childhood and the disease is associated with progres-
sive muscle weakness and wasting encompassing distal and proximal parts of the upper
and lower limbs. Some patients affected with CMT-GDAP1 are wheelchair-bound [1,2].
To date, more than 100 mutations have been identified in GDAP1 from patients exhibiting
a CMT phenotype. The vast majority of them are inherited as autosomal recessive traits,
however dominant mutations are also described [3].
GDAP1 was first identified in 1999 as one of a series of ten transcripts, the expression
of which are highly elevated upon ganglioside-induced differentiation of murine neuronal
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cell lines [4]. In 2002, two independent groups identified mutations in GDAP1 that led to
the rare polyneuropathy, CMT disease [5,6]. Over the last 20 years, knowledge relating to
the structure and function of GDAP1 has increased significantly. However, many aspects
of its role in cell function and, in particular, of the pathogenesis of CMT-associated GDAP1
mutations are still not understood [3,7]. This lack of understanding hampers efforts to
develop an efficient therapy. Currently, there is no efficient treatment for CMT-GDAP1 and,
furthermore, no single substance has reached clinical or even pre-clinical testing.
GDAP1 is an outer-mitochondrial membrane protein [8,9] with primary sequence
homology to members of the glutathione S-transferase (GST) superfamily [6,10]. However,
its activity as a GST is highly questionable [9,11,12]. The GDAP1 protein is involved in
many aspects of mitochondrial physiology [3,7]. In addition, a number of studies suggest
that GDAP1 with the junctophilin-1 is involved in the regulation of calcium homeostasis
in cells [13–15]. It is therefore interesting that heterologous expression of GDAP1 in yeast
suppresses the calcium hypersensitivity of a strain that lacks CSG2 gene (csg2∆), encoding
the protein required for the formation of complex sphingolipids [16]. It was also reported
that GDAP1 is targeted to peroxisomes, where it regulates their morphology [17].
Impairment of mitochondrial homeostasis is seen as the major cause of the CMT-
GDAP1 disease. Phenotypes associated with a GDAP1 mutation include: disruption of
mitochondrial fission-fusion events; changes in mitochondrial distribution; impairment of
the mitochondrial transmembrane potential; an increase in reactive oxygen species levels; a
reduction in glutathione content; and an alteration of mitochondrial bioenergetics [8,18–23].
Additionally, expression of the mutated GDAP1-Gly327Asp and GDAP1-Leu239Phe alleles in
yeast cells increases the rate of DNA escape from mitochondria to the nucleus, indicating an
abnormality in mitochondrial functioning [16]. Recently, Fernandez-Lizarbe and coworkers
have used the GDAP1 knockout (GDAP1 -/-) mouse model to show that inflammation
in the spinal cord and sciatic nerve contributes to the pathophysiology of GDAP1-related
CMT [24].
The Golgi apparatus (henceforth referred to simply as the Golgi) is a membrane-bound
organelle that plays a central role in the trafficking, processing, and sorting of proteins
and lipids. It is often located adjacent to the nucleus in vertebrate cells and consists of
several flattened cisternae piled on top of each other and aligned in parallel into com-
pact stacks. Tubular membranes interconnect these stacks to form a ribbon-like network.
However, in certain unicellular eukaryotes, including the yeast Saccharomyces cerevisiae,
the Golgi structures appear as single, isolated cisternae randomly distributed throughout
the cytoplasm [25,26]. The Golgi is highly polarized; proteins and lipids from the endo-
plasmic reticulum (ER) are transported to the cis compartment of the Golgi, then exported
through medial- to the trans-Golgi. In the trans-Golgi network (TGN), the cargo is separated,
sorted and targeted to other cellular structures including the endosomes, lysosomes and
plasma membrane or exported outside of the cell [27]. When passing through the Golgi
compartments, cargo molecules are modified and processed. Individual sub-compartments
of the Golgi stacks contain unique sets of resident proteins, responsible for maintaining the
architecture and function of the Golgi and for modification of cargoes [26,27].
To the best of our knowledge, the present work shows for the first time that, in addition
to its roles in mitochondrial and peroxisomal function, GDAP1 also influences the structure
and probably the functioning of the Golgi. Decreased levels of GDAP1 protein in SH-SY5Y
and HeLa cell lines results in changes in the Golgi morphology as observed by transmission
electron microscopy (TEM). What is more, the reduction of the native levels of GDAP1
in HeLa cells alters the maturation and localization of the trans-Golgi protein TGN46. In
yeast cells, expression of the GDAP1-Leu239Phe gene specifically affects the distribution of
trans-Golgi protein Sec7, suggesting changes in the organization of the Golgi network and
demonstrating that yeast is a convenient model in which to study CMT-GDAP1.
To further dissect the role of GDAP1 in the cell and especially how it influences Golgi
function, we used a yeast GDAP1-model. Firstly, we investigated the mechanism by which
the calcium hypersensitivity associated with csg2∆ strain is suppressed by human GDAP1.
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We have found that GDAP1-mediated suppression of the calcium sensitivity of csg2∆
does not require ongoing sphingolipid synthesis. This effect is not dependent on normal
functioning of the Golgi, as expression of GDAP1-Leu239Phe, which results in alterations to
the Golgi network in yeast, is as beneficial as the expression of wild type GDAP1. Secondly,
we decided to screen a drugs library for substances that, similarly to GDAP1, suppress
the grown defect of csg2∆ on calcium-containing medium. The drugs that exhibited a
suppressive effect suggest that the effects of GDAP1 on cell function are mediated via
different pathways. In summary, we have shown that GDAP1 mutations affect the structure
and probably the functioning of different molecular pathways that affect the TGN.
2. Results
2.1. GDAP1 Protein Levels Influence Mitochondria and Golgi Morphology in SH-SY5Y Cells
The molecular function of GDAP1 in cells has not been determined. Here we inves-
tigated the effect of altering GDAP1 expression levels (either reduced or overexpressed)
in the SH-SY5Y cell line derived from human neuroblastoma. Neuron-derived cells are a
suitable model to study GDAP1-associated effects due to the involvement of GDAP1 in the
pathogenesis of peripheral neuropathies. To reduce expression of GDAP1, RNA silencing
was used. Western blot analysis revealed that, 24 h after siRNA transfection, the level of
GDAP1 was markedly reduced in comparison to the control. This reduction of expression
could still be observed, albeit less so, 48 h post-transfection (Figure 1a).
Figure 1. GDAP1 levels in SH-SY5Y cells determines the morphology of mitochondria and the Golgi. (a) The level of
GDAP1 following 24 or 48 h of siRNA silencing, and after GDAP1 overproduction. Western blot analysis of total cell extracts
using an anti-GDAP1 antibody. (b) Electron micrographs presented mitochondrial morphology in cells overexpressing
GDAP1. Scale bar 2 µm. (c) Quantification of results from (b). (d) Morphology of the Golgi following GDAP1 gene silencing
in SH-SY5Y cells on electron micrographs. Scale bar 500 nm.
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It can also be seen that overexpression of GDAP1 was very effective (Figure 1a). The
influence of GDAP1 concentration on the structure of the mitochondria and Golgi was
investigated using transmission electron microscopy (TEM).
It was previously shown that GDAP1 is involved in the maintenance of mitochondrial
morphology. Thus, we began by analyzing the general appearance of these organelles in
cells with altered levels of GDAP1. Figure 1b shows that overexpression of GDAP1 affects
mitochondrial size and shape: mitochondria were smaller and rounder compared to those
in the control cells. This finding is in agreement with previously published data [8,28]. The
effect of GDAP1 gene silencing on mitochondria was not evident. We cannot discriminate
between cells without and with significant GDAP1 silencing (Figure 1a). We were unable
to determine GDAP1 levels for individual cells and thus could not associate mitochondrial
morphology with a specific GDAP1 concentration. Surprisingly during the examination
of the TEM images, we found that even a partial reduction of GDAP1 levels resulted in
alterations to Golgi morphology; the cisternae were more irregular in shape and the ends
of the stacks are denser (Figure 1d). Thus, TEM analysis of a neuroblastoma cell line
suggested that GDAP1 protein may also influence the structure and function of the Golgi.
2.2. Exogenous Expression of Particular GDAP1 Variants Affects the Endogenous GDAP1 Protein
Levels in HeLa Cells
As the previous experiment pointed to the involvement of GDAP1 in maintenance
of the Golgi structure, we hypothesized that the pathogenic effects of GDAP1 mutations
may, at least partially, result from a failure of this organelle. To test this hypothesis, we
examined the influence of selected GDAP1 variants on Golgi morphology. The SH-SY5Y
cell line is characterized by a high expression of endogenous GDAP1, which makes it
impossible to observe the effects of recessive GDAP1 gene variants. Thus, for further
experiments, we used the HeLa cell line that was previously used to characterize GDAP1
mutants [12,21,29]. Six GDAP1 mutations were analyzed (Figure 2a) based on the following
criteria: (i) whether the GDAP1 mutation is inherited as an autosomal recessive (4 alleles)
or autosomal dominant trait (3 alleles), (ii) frequency of the mutations (GDAP1-Leu239Phe)
in the population (recurrent mutation) and (iii) availability of clinical data for phenotypes
of CMT disease associated with a specific mutation. The GDAP1-Pro153Argfs*19 mutation
has never been identified in a patient with CMT; it was generated by mutagenesis and was
included here to represent the frame-shift, loss of function mutations of GDAP1.
To study the effect of expressing selected GDAP1 alleles in HeLa cells, we initially
analyzed the levels of mutant GDAP1 proteins. Surprisingly, it was observed that following
transfection with vector only, or with vector bearing wild-type GDAP1 or with specific
GDAP1 alleles (namely GDAP1-Pro153Argfs*19, GDAP1-Gln218Glu and GDAP1-Leu239Phe)
the total level of GDAP1, including the endogenously expressed protein, dropped markedly
(Figure 2b). However, following expression of the GDAP1-Gly327Asp, GDAP1-Glu222Lys
and GDAP1-His123Arg alleles, the level of GDAP1 protein increased to a level comparable
to that observed for the SH-SY5Y cell line (Figure 2b). Based on this observation, we
concluded that GDAP1 variants may be assigned into two groups. The first group displays
the same effect observed for expression of wild type GDAP1—silencing of the endogenous
GDAP1. The second group includes certain variants, expression of which resulted in the
overproduction of GDAP1.
2.3. A Reduction of GDAP1 Expression Alters Golgi Morphology in HeLa Cells
Expression of some GDAP1 variants in HeLa cells clearly leads to a reduction of total
GDAP1. We checked if, similarly to neuroblastoma cells, a decreased amount of GDAP1 in
HeLa cells also resulted in alterations to the Golgi morphology. TEM analysis revealed that
intact Golgi were visible in about 20% of control cells. Approximately 50% of the control
cells exhibited an altered Golgi morphology; one that takes the form of cisternae plus
vacuoles (altered type I). The fraction of cells—in which the Golgi in the form of cisternae
is invisible—was also recorded (altered type II). In cells expressing the GDAP1-Leu239Phe
allele (with a reduced GDAP1 level) the number of cells with distinguishable cisternae (both
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unaltered and altered type I) decreased while the percentage of cells in which the Golgi
took the form of vacuoles only (altered type II) increased (Figure 3). The cells expressing
GDAP1-Gly327Asp (resulting in overexpression of GDAP1) also exhibited an altered Golgi
morphology, but the changes were minor compared to those observed in cells expressing
GDAP1-Leu239Phe. Expression of GDAP1-Gly327Asp resulted in a slight increase in the
number of cells in which the Golgi took the form of vesicles (Figure 3).
Figure 2. Expression of various GDAP1 alleles in HeLa cells affects the level of endogenous GDAP1. (a) Schematic
representation of GDAP1 structure including amino acid residue substitutions that result from the GDAP1 variants of
autosomal dominant (AD; above schematic) or autosomal recessive (AR; below schematic) modes of inheritance. (b) Western
blot analysis using anti-GDAP1 antibody. Shown are total cell extracts from non-transfected HeLa cells (first lane from left),
HeLa cells transfected with empty vector ([-]) or HeLa cells transfected with vectors carrying the indicated GDAP1 variants.
The samples were normalized for protein loading using Ponceau S staining.
2.4. A Reduction of GDAP1 Expression Results in Changes to Post-Translational Modifications of
TGN46
We asked if alterations of the Golgi structure in HeLa cells is also manifested at a
molecular level as changes in the levels or modifications of Golgi proteins. Initially we
analyzed the levels of Golgi proteins that are characteristic of the cis- and trans-Golgi
regions. There were no statistically significant changes in the level of the cis Golgi marker,
GM130, but changes in the pattern of bands of the trans-Golgi marker, TGN46, were
observed (Figure 4).
TGN46 is a type I transmembrane glycoprotein, which migrates as several bands
during electrophoresis. The >110 kDa form is the mature sialylated protein. Western blot
analysis revealed that the expression of some GDAP1 mutant alleles resulted in a drop
in the endogenous GDAP1 level, and this correlates with a change to the pattern of post-
translational modification of TGN46. In cells expressing GDAP1, GDAP1-Pro153Argfs*19,
GDAP1-Gln218Glu and GDAP1-Leu239Phe, TGN46 did not fully mature; the slower mi-
grating forms, shown previously to be sialylated forms, were absent. A 70 kDa form was
more pronounced in the cells expressing the mutant alleles (Figure 4). Thus, a reduction
in GDAP1 levels alters some processes carried out in the Golgi, reflected by changes in
TGN46 maturation.
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Figure 3. Expression of mutant GDAP1 variants affects the morphology of the Golgi in HeLa cells.
(a) Transmission electron microscope analysis of the Golgi in non-transfected HeLa cells (CTRL)
or in HeLa cells transfected with a vector carrying GDAP1-Gly327Asp or GDAP1-Leu239Phe alleles.
Electron micrographs of representative examples of Golgi structures observed in HeLa cells. Black
arrowheads indicate the cisternae of the Golgi. Scale bar 750 nm. (b) Fraction of cells [as percentage
of counted cells] with types of Golgi ultrastructure indicated. Statistical analysis was performed
on data from three independent experiments using one-way ANOVA and Bonferroni’s correction:
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Figure 4. The level of GDAP1 protein correlates with changes in the pattern of TGN46 modifications.
Western blot analysis of total cell extracts from not transfected HeLa cells (far left lane), transfected
with empty vector ([-]) or vectors bearing variants of GDAP1 (as indicated). Western blots performed
using antibodies against GDAP1 or against the Golgi proteins GM130 and TGN46. The black arrow
indicates immature TGN46, the grey arrow shows mature, modified forms.
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2.5. Localization of TGN46 Is Altered in HeLa Cells Expressing the GDAP1-Leu239Phe Variant
Post-translational modification of proteins regulates their activity, stability and local-
ization. As discussed above, HeLa cells with a reduced level of GDAP1 exhibited alterations
in expression and maturation of TGN46. We therefore decided to test if these alterations
also affected the localization of TGN46 in cells with expression of two chosen mutant alleles
as the representatives of two different GDAP1 expression level. These mutations are the
most common one, GDAP1-Leu239Phe, and GDAP1-Gly327Asp, which results in disturbing
GDAP1 targeting to the mitochondrial membrane [2,30]. In order to visualize the mor-
phology of the Golgi we immunostained the GM130, GORASP2 and B4GALT3 proteins.
All proteins were observed using confocal microscopy. In the control HeLa cells, GM130
( cis-Golgi marker), GORASP2 (medial-Golgi), B4GALT3 (TGN) and TGN46 (TGN), were
present in structures near one pole of the nucleus, as expected for Golgi proteins. A similar
localization of these proteins was observed for cells expressing the GDAP1-Gly327Asp allele.
In contrast, in cells expressing GDAP1-Leu239Phe, the distribution of TGN46 was altered; it
was localized in tubular structures (Figure 5). This mislocalization of TGN46 could arise as
a consequence of altered post-translational modification or, conversely, the mislocalization
could be responsible for alterations in post-translational modification of TGN46.
2.6. Yeast Cells Transformed with the GDAP1-Leu239Phe Gene Allele Exhibit Changes in the
Localization of Sec7
Recently, we have demonstrated that it is possible to determine the effects of GDAP1
expression on yeast cell physiology. In addition we showed that expression of different
GDAP1 alleles may have different effects on the functioning of yeast cells [16]. We hypothe-
sized that the effects of a GDAP1 variant on the Golgi were similar for both the HeLa and
yeast cell models. Thus, we decided to check if expression of the same GDAP1 alleles as in
HeLa cells: GDAP1, GDAP1-Gly327Asp and GDAP1-Leu239Phe could alter the localization
of Golgi proteins in yeast cells. In order to compare models, we monitored two different
Golgi marker proteins, Sed5 and Sec7, tagged with red fluorescence protein (mRFP). Sed5
is a cis-Golgi marker while Sec7 serves as a TGN marker [31]. In yeast cells, the Golgi
structure differs from the classical cisternae stacks observed in mammalian cells. Yeast
Golgi takes the form of dispersed cisternae throughout the cytoplasm, observed as single
puncta. Confocal microscopy revealed that the number of Sed5-mRFP spots was similar in
all examined transformants (Figure S1). In contrast, cells expressing GDAP1-Leu239Phe had
a higher number of Sec7-mRFP containing puncta (Figure 6). This suggests that the yeast
trans-Golgi could also be affected by expression of GDAP1-Leu239Phe. As the phenotypes
observed in HeLa cells are similar to those observed for yeast cells, it raises the possibility
that yeast cells could be used to further investigate the influence of GDAP1 variants on
Golgi structure and function.
2.7. GDAP1-Mediated Suppression of the Calcium Sensitivity of csg2∆ Does Not Require Ongoing
Sphingolipid Synthesis
The effect of GDAP1 gene expression on yeast cell physiology is apparent when it is
expressed in a csg2∆ mutant. This expression results in suppression of the calcium sensitiv-
ity of the csg2∆ mutant and different GDAP1 variants either retain or lose this suppressive
ability [16]. Csg2 is a Golgi localized protein, which is required for mannosylation of
inositolphosphorylceramide i.e., the formation of complex sphingolipids (Figure 7a).
It was shown that Csg2 is also required for the efficient retention of some medial-
Golgi enzymes [32]. To uncover the molecular mechanisms underlying GDAP1-mediated
suppression of calcium sensitivity in a csg2∆ mutant, and to test if the observed effect is
Golgi-dependent, we asked if ongoing sphingolipid synthesis is necessary for the efficiency
of GDAP1-mediated suppression. Furthermore, we asked if the GDAP1-Leu239Phe variant,
which affects trans-Golgi protein localization in yeast, improves the growth of the csg2∆
mutant in the presence of calcium ions. We examined if the addition of myriocin, which
blocks the first enzyme of the sphingolipid synthesis pathway, abolishes GDAP1-mediated
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suppression. To answer these questions the growth of the csg2∆ mutant on plates containing
calcium ions was compared to growth on plates containing calcium ions and myriocin. The
growth of csg2∆ was reduced by the addition of calcium ions and further by the addition
of myriocin. When csg2∆ was transformed with GDAP1 or the GDAP1-Leu239Phe allele, it
grew better than when transformed with an empty plasmid or with the GDAP1-Gly327Asp
allele (Figure 7b). This suggests that the presence of GDAP1 protein reduces the toxicity of
calcium ions in a csg2∆ mutant in a manner that does not involve ongoing sphingolipid
biosynthesis. Furthermore, this suggests that the GDAP1-based suppression is not related
to the effects of the GDAP1 protein on the Golgi; the expression of GDAP1-Leu239Phe,
which changes the modification and localization of TGN46 in HeLa cells and number of
Sec7-mRFP containing structures in yeast cells, has a positive effect on the growth of the
csg2∆ mutant, which already has an altered Golgi apparatus.
Figure 5. The localization of TGN46, a protein of the trans-Golgi network, is altered in HeLa cells expressing the GDAP1-
Leu239Phe allele. The confocal microscopy images show the localization of GM130, GORASP2, B4GALT3 and TGN46
proteins in the control HeLa cells or in HeLa cells expressing the GDAP1-Gly327Asp or GDAP1-Leu239Phe alleles. All
proteins were visualized by indirect immunofluorescence. Nuclear DNA was stained with DAPI.
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Figure 6. The expression of GDAP1 variants in yeast cells influences localization of Sec7-mRFP, the trans-
Golgi network marker protein. Yeast cells carrying the SEC7-mRFP-containing plasmid were observed
using confocal microscopy. The number of Sec7-mRFP puncta in a single cell was determined. Error bars
represent standard deviation for three repeats. Statistical analysis was performed on data from three
independent experiments using t-Test. * p-value < 0.05 ** p-value < 0.01.
Figure 7. Expression of GDAP1 or the GDAP-Leu239Phe allele suppresses the sensitivity of the csg2∆ mutant to Ca2+ ions
even in the presence of myriocin. (a) Schematic representation of the sphingolipid biosynthesis pathway. The step inhibited
by myriocin is indicated. (GDP) guanosine diphosphate. (b) The growth of wild-type and csg2∆ mutant strains transformed
with empty vector ([-]), or vectors carrying the cDNA of GDAP1, ([GDAP1]) or GDAP1 variants ([GDAP1-Gly327Asp] and
[GDAP1-Leu239Phe]) was compared on YPD media or YPD containing 0.4 M calcium chloride (+CaCl2) or 0.4 M CaCl2 and
1 µM myriocin (+CaCl2 + Myriocin).
2.8. Screening a Drug Library Using the Calcium Hypersensitivity of the csg2∆Strain Revealed
Ibuprofen Piconol as an Active Compound
We have already ruled out the influence of GDAP1 protein on the sphingolipid
biosynthesis pathway and related GDAP1’s effects to changes in the structure of the Golgi.
The molecular mechanism by which GDAP1 acts in csg2∆ cells is still unknown. For a
further dissection of the GDAP1-dependent suppression of calcium hypersensitivity in
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a csg2∆ mutant, we used a chemical suppressor screen, assuming that we would find
a compound that exerts an effect similar to that caused by the expression of GDAP1.
Identification of such a compound, coupled with its mechanism of action, will be used to
determine the role of GDAP1. We adapted the Ca2+ ion sensitivity phenotype of a csg2∆
mutant for use in a drug screen (Figure 8), in order to identify molecules that suppress
the calcium hypersensitivity associated with csg2∆. We screened the Prestwick drug
repurposing library (Prestwick Chemical Library) previously used in such screens [33–35],
which contains drugs approved for use in humans.
Figure 8. Ibuprofen piconol is a chemical suppressor of the csg2∆ growth defect on media supplemented with Ca2+ ions.
The csg2∆ cells were plated on YPD + 0.5 M CaCl2. Compounds from the Prestwick library were applied on filter discs (2 µL
of 10 mM solution in DMSO). DMSO, a solvent, was used as a negative control. The csg2∆ [GDAP1] strain was spotted as a
positive control. Plates were incubated for 3–5 days at 28 ◦C.
Library compounds were applied to filter discs on top of solid media. Active com-
pounds were identified after 3–5 days by observation of growth zones around the filter.
Two drugs were identified as suppressors of the csg2∆ growth defect on Ca2+ ion containing
media. The first was a previously identified chemical suppressor: cyclosporine A. The sec-
ond was ibuprofen piconol (Figure 8), a nonsteroidal anti-inflammatory agent that inhibits
synthesis of prostaglandins in mammalian cells, but is also regarded as a phospholipase
inhibitor. In summary, expression of GDAP1 suppresses csg2∆, not through biosynthesis of
sphingolipids, but via another conserved pathway, most probably connected with calcium
homeostasis, inhibition of phospholipase A or both.
3. Discussion
Although almost 20 years have passed since GDAP1-associated CMT disease was first
described, its molecular pathogenesis is still not understood. The molecular pathogenesis of
CMT-GDAP1 disease has been linked to a mitochondrial pathology and to disturbances in
calcium homeostasis. The uncertainty as to the underlying causes of the pathogenesis mean
that even experimental therapies are not possible. Clinical trials for the treatment of patients
suffering from other types of CMT have been conducted and published, which suggests
a road map for the future [36,37]. The main issue here is the diversity of phenotypes
caused by different mutations in GDAP1. In the present study, we have shown two
additional molecular phenotypes associated with mutations in GDAP1. Here we analyzed
six mutations in GDAP1, three resulted in lower levels of GDAP1, and the other three did
not. In addition, the mutations that influence GDAP1 levels, such as GDAP1-Leu239Phe,
also affected the morphology of the Golgi. These alterations in morphology are visualized
as a conversion of Golgi structures (from cisternae to vesicles) as detected by TEM in
neuroblastoma as well as in HeLa cells. These changes are accompanied by changes in the
modification and localization of TGN46, a protein of the TGN. The impact of GDAP1 on the
Golgi was also apparent in yeast cells expressing GDAP1-Leu239Phe. We then used yeast
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model to screen for drugs that could restore normal functioning in the absence of GDAP1.
To the best of our knowledge, this study is the first report of a link between disturbances in
the Golgi and the molecular pathogenesis of Charcot-Marie-Tooth disorders.
Initial studies suggested that GDAP1 expression was limited to the neural cell lines.
Later studies suggested that this is not the case: human fibroblasts contain about 2.6%
GDAP1 mRNA levels found in motor neurons and at least some GDAP1 mutations result
in a dramatic reduction of GDAP1 mRNA expression in CMT patients fibroblasts [20].
Interestingly, the same effect, the very low levels of GDAP1, is observed in the fibroblasts
of patients carrying the homozygous GDAP1-Leu239Phe and GDAP1-Arg273Gly muta-
tions [20] and in HeLa cells transfected with a plasmid expressing the GDAP1-Leu239Phe
variant. This similarity between the molecular effects of the GDAP1-Leu239Phe mutation in
two divergent cell lines (fibroblasts biopsied taken from patient and HeLa cells) supports
our use of HeLa cells in these studies. Thus, mutations that reduce GDAP1 levels have a
similar effect to loss of function mutations or even knockout mutations. It is interesting
to establish how the level of GDAP1 correlates with the severity of clinical manifestation.
At least in other CMT type diseases caused by mutations in the IGHMBP2 gene, there is a
correlation between the IGHMBP2 level and severity of the disease [38].
The TGN is a particularly dynamic structure: microscopic observations show the
continuous formation of tubules and vesicles in this part of the Golgi. This process requires
tubulin dimers. Tubules appear to be drawn from the TGN along the microtubules. Once
formed, the vesicular tubular carriers move towards the periphery of the cell, transported
along the microtubules [39]. It is proposed that the defects in microtubule-dependent traf-
ficking lead to neurodevelopmental and neurodegenerative diseases including Alzheimer’s
disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS; also known as Motor Neu-
rone Disease or Lou Gehrig Disease) or traumatic brain injury. Recent studies highlight the
use of microtubule stabilizing agents as potential drugs for improving axonal transport and
therefore nerve function in these diseases [40]. Noteworthy, the pathogenesis of CMT2Z
caused by mutations in MORC2 gene could be also linked to disturbances in trafficking
along microtubules [41]. Beta-tubulin is known to interact with GDAP1 [14,15], therefore
changes in the interaction between beta-tubulin and GDAP1, caused by mutations in
GDAP1, could impact microtubules and subsequently TGN structure and function. How-
ever, the changes caused by mutations in GDAP1 are subtle and impact only the TGN. In
contrast, for Alzheimer’s disease, Parkinson’s disease and ALS, fragmentation of the whole
Golgi has been reported [42]. The number of reports showing fragmentation of the Golgi
limited to the TGN is scarce. In HEK293 cells expressing Rab71 and in a LRRK2 mutant (a
model for Parkinson’s disease), Golgi fragmentation was limited to the TGN with the cis-
and medium-Golgi segments remaining intact [43]. A similarly specific TGN fragmentation
was observed for Vero76 cells infected with Rickettsia rickettsii [44]. In Parkinson’s disease,
the Golgi dispersion was mediated by Rab7L1 GTPase while in the Rickettsia infected cells,
dispersion was mediated by RARP2 (Rickettsial Ankyrin Repeat Protein 2) suggesting
heterogeneous molecular mechanisms for TGN disruption [43–45]. Moreover, recent stud-
ies have demonstrated that the Golgi acts as a platform for the formation of signaling
complexes triggering the inflammatory response [46] and that the disassembly of TGN is
a crucial event in the activation of the NRPL3 inflammasome. Diverse NRPL3 activators
trigger this response, but the cis- and the medial-Golgi remain intact throughout [47]. In the
present study, we have shown for the first time that the TGN may also be disrupted in CMT
disease or at least in some CMT subtypes caused by mutations within GDAP1. We have
revealed this in a series of three independent experiments encompassing neuroblastoma,
HeLa and yeast cells. Similarly to the previously reported studies in which selected TGN
disruption was observed, the Golgi disturbance we detected in HeLa cells transfected with
GDAP1-Leu239Phe was limited to the TGN only. Additionally impaired function of the
TGN, at the very least, results in changes to the glycosylation pattern and localization
of TGN46. Meanwhile, the localization patterns of cis-, medial- and other TGN proteins
(GM130, GORASP2 and B4GALT3, respectively) remain intact, unchanged from the pattern
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observed for control cells. Our finding that the Golgi is affected in CMT sheds new light
on the pathology of CMT-GDAP1, which, so far, has only been associated with mitochon-
drial dysfunction encompassing mitochondrial fission/fusion processes; mitochondrial
transport and impaired oxidative phosphorylation [3]. How some GDAP1 gene mutations
may selectively affect TGN46, but not B4GALT3 in the TGN of HeLa cells remains unclear.
However, there is evidence that the TGN is organized into distinct sub-compartments,
marked by specific TGN proteins. Examples of the specific localization of proteins include
the distinct localizations of ATP7A, a copper transporting ATPase, and TGN46 [48]. An-
other example is the localization of golgins: proteins that function as molecular tethers
during the docking of transport vesicles to a target membrane during the maintenance of
stacked cisternae structures in the Golgi. Two such golgins, GCC88 and GCC185, localize
to a common TGN sub-compartment. Alpha-2, 6-sialyltransferase also localizes to this
sub-compartment but TGN46 is absent. This sub-compartment is distinct from that which
contains p230/golgin-245 and golgin-97 [49]. The mechanism/pathway by which GDAP1
influences the modification and localization of TGN46 remains to be studied. It is also
possible that mutations in the DNM2 gene encoding a dynamin and causing CMTIB may
affect the structure of the TGN as well as they affect the receptors endocytosis [50]. The
same may be true for mutations in the SH3TC2 gene causing CMT4C. These mutations also
affect endocytosis, which may reflect a general disturbance of intracellular transport from
the TGN and in later stages [51]. To find the molecular mechanism leading to changed
TGN46 localization, the molecular partners of GDAP1 need to be identified. From our
studies, we predict that the molecular pathway by which GDAP1 influences TGN structure
and function is conserved. Similarly to what was observed in HeLa cells, the expression of
GDAP1-Leu239Phe in yeast cells changed the distribution of Sec7-mRFP (a TGN marker)
while localization of Sed5 (a cis-Golgi marker) remained unchanged. This conservation
allows us to use the yeast model to identify the molecular partners of GDAP1 and to
uncover the pathways that influence TGN functioning.
The GDAP1 mRNA is one of 10 mRNAs that are highly expressed in the Neuro2a cell
line (a mouse neuroblastoma cell line) following neurite-like differentiation. Differentiation
is achieved by transfection of these cells with a cDNA encoding the gene for the GD3
synthase [4]. The GD3 synthase is a Golgi membrane protein that catalyzes the formation
of GM3 ganglioside, a ceramide-based glycolipid. In yeast, the sphingolipid composition is
quite simple: yeast contain three inositol-containing complex sphingolipids only with one
mannose. Csg2 influences the mannosylation of inositolphosphorylceramide [52]. Here we
present evidence that the effect of GDAP1 expression in a csg2∆ mutant is most likely not
related to its effect on the complex sphingolipid biosynthetic pathway and, by extension,
on Golgi structure. Two lines of evidence from our yeast study suggest such a conclusion.
Firstly, the addition of myriocin, which inhibits the first enzyme of the sphingolipid
biosynthesis pathway, does not abolish the suppression of a csg2∆ mutant through the
expression of GDAP1. Secondly, a comparison of the effect of GDAP1 expression with the
known action of chemical suppressors, isolated in a screen, suggests an indirect effect. The
identification of cyclosporine A in the drug screen suggests the involvement of calcium
homeostasis. It has been shown that GDAP1-knockouts in either human neuroblastoma
SH-SY5Y cells or in mice motor neurons exhibit a defect in store-operated calcium entry
(SOCE), a calcium cell-entry pathway [14,15]. This phenotype is linked to an observed
mislocalization of mitochondria [14]. The selection of ibuprofen as a chemical suppressor
mimicking the effect of GDAP1 expression in the csg2∆ mutant suggests that there may
be an additional mechanism. Ibuprofen is the most interesting candidate drug due to
the recent findings of Fernandez-Lizarbe et al. regarding neuroinflammation in GDAP1-
knockout mice [24]. The authors of this elegant study have demonstrated the presence
of elevated levels of some proinflammatory mediators (TNF-α and pERK, and the C1qa
and C1qb proteins of the complement system) supporting the role of inflammation in
the pathogenesis of CMT-GDAP1 disease. Ibuprofen is an anti-inflammatory agent that
is able to restore growth of the csg2∆ mutant yet there are no inflammatory processes
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in yeast cells. This suggests that the initial stages (i.e., biochemical pathways) of the
inflammatory process are present in yeast cells. We speculate that this process is related to
the maintenance of TGN structure. Regardless of the mechanism of action of ibuprofen, the
presence of an inflammatory response in GDAP1-/- mice classify this compound as one of
the first potential drugs with which to treat CMT-GDAP1 disease. Given the relatively low
number of adverse effects associated with ibuprofen, its use in experimental CMT-GDAP1
therapy is quite realistic.
In conclusion, our work shows that the mitochondrial protein GDAP1 involved in
the pathology of CMT is associated with changes in a distinct cell compartment, the TGN.
These changes could be responsible for inducing inflammation. Drugs with different
mechanisms of action were shown to have activity in the yeast CMT-GDAP1 model. This
indicates that multiple molecular pathways can compensate for the lack of GDAP1. Finally,
ibuprofen is an encouraging candidate for the treatment of CMT-GDAP1 disease.
4. Materials and Methods
4.1. Yeast Strains, Media and Growth Conditions
The yeast Saccharomyces cerevisiae strains used in this study were BY4741 MATa his3∆1
leu2∆0 met15∆0 ura3∆0 and BY4741 csg2∆. Yeast cultures were grown at 28 ◦C or at room
temperature in YPD medium (1% yeast extract, 2% peptone, 2% glucose) or in complete
synthetic medium (SC) (0.67% yeast nitrogen base with ammonium sulfate without amino
acids, 2% glucose with complete supplement mixture). For growth tests, the optical
cell density (OD600) was determined and cultures were diluted with SC-leu medium to
OD600 ≈ 1. Aliquots of 10-fold serial dilutions of cells were spotted on solid YPD media
plates supplemented as indicated. Plates were incubated at room temperature for the
number of days indicated.
Neuroblastoma cell line SH-SY5Y (gift from M.Szeliga MMRC PAS) was maintained in
DMEM/F12 (Sigma-Aldrich, Saint Louis, MI, USA) containing 10% FBS (Thermo Fisher Sci-
entific, Waltham, MA, USA), 100 IU/mL penicillin, and 100 µg/mL streptomycin (Thermo
Fisher Scientific), + 1% Non-Essential Amino Acids (NEAA) (Sigma-Aldrich) and uridine
1mg/mL (Sigma-Aldrich). The HeLa cell line from American Type Culture Collection
(ATCC, Manassas, VA, USA) was grown in Dulbecco’s modified Eagle’s medium (DMEM
high glucose, GlutaMAX, Thermo Fisher Scientific) containing 10% FBS (Thermo Fisher
Scientific), 100 IU/mL penicillin, and 100 µg/mL streptomycin (Thermo Fisher Scientific)
and uridine 1mg/mL (Sigma-Aldrich) in a humidified tissue culture incubator at 37 ◦C
and 5% CO2 atmosphere.
For transmission electron microscopy analysis (TEM), SH-SY5Y and HeLa cells were
cultured at the seeding density of 1 × 105 cells on Nunc Thermanox Coverslips (ø13 mm,
Thermo Fisher Scientific, nr cat.: 174950), placed into 24-well plates and incubated for 24 h
until they reached approximately 70–80% confluency.
4.2. Cell Transfection and GDAP1 Silencing
HeLa and SH-SY5Y cells were transfected using the pIRES2-AcGFP1 Vector with
Viromer Red (Lipocalyx, Halle, Germany) according to the manufacturer’s recommenda-
tions with the standard transfection scale. In all cases, the medium was changed 48 h
after transfection. The resulting transfectant HeLa and SH-SY5Y cells were cultured in an
appropriate medium with 500 µg/mL G418 (Lab Empire, Rzeszów, Poland) for 2 weeks.
For the generation of a GDAP1-silenced SH-SY5Y cell line, cells were seeded on 24-
well plate to a confluency of about 70–80% and transfected using 1.6 µL of siRNA (10 µM
solution) (Qiagen, Valencia, CA, USA) per well and Lipofectamine 3000 (Thermo Fisher
Scientific) as recommended by the manufacturer. Clonal cell lines were tested for GDAP1
silencing by Western blot.
4.3. Plasmids and DNA Manipulations
The plasmids used in this study are listed in Table 1.
Int. J. Mol. Sci. 2021, 22, 914 14 of 18
Table 1. Plasmids used in this study.
Name Description Source
Yeast Plasmids:
p425-PTDH3 2µ; LEU2 [53]
p425-PTDH3-GDAP1 2µ; LEU2; GDAP1 [16]
p425-PTDH3-GDAP1m2
2µ; LEU2; GDAP1 c.980G > A;
p.Gly327Asp [16]
p425-PTDH3-GDAP1m5
2µ; LEU2; GDAP1 c.715C > T;
p.Leu239Phe [16]
Sec7-mRFP URA3; SEC7-mRFP [31]
Sed5-mRFP URA3; SED5-mRFP [31]
Mammalian Expression Plasmids:
pCMV6-XL5-GDAP1 Human Untagged Clone GDAP1 cDNA OriGene
pCMV6-XL5-GDAP1m1 GDAP1 c.456delC; p.Pro153Argfs*19 This study
pCMV6-XL5-GDAP1m2 GDAP1 c.980G > A; p.Gly327Asp This study
pCMV6-XL5-GDAP1m3 GDAP1 c.652C > G; p.Gln218Glu This study
pCMV6-XL5-GDAP1m4 GDAP1 c.664G > A; p.Glu222Lys This study
pCMV6-XL5-GDAP1m5 GDAP1 c.715C > T; p.Leu239Phe This study
pCMV6-XL5-GDAP1m6 GDAP1 c.368A > G; p.His123Arg This study
pIRES2-AcGFP1 Bicistronic vector with GFP TAKARA Bio
pIRES2-AcGFP1-GDAP1 GDAP1 WT This study
pIRES2-AcGFP1-GDAP1m1 GDAP1 c.456delC; p.Pro153Argfs*19 This study
pIRES2-AcGFP1-GDAP1m2 GDAP1 c.980G > A; p.Gly327Asp This study
pIRES2-AcGFP1-GDAP1m3 GDAP1 c.652C > G; p.Gln218Glu This study
pIRES2-AcGFP1-GDAP1m4 GDAP1 c.664G > A; p.Glu222Lys This study
pIRES2-AcGFP1-GDAP1m5 GDAP1 c.715C > T; p.Leu239Phe This study
pIRES2-AcGFP1-GDAP1m6 GDAP1 c.368A > G; p.His123Arg This study
GDAP1 cDNA was subcloned from pCMV6-XL5 GDAP1 (NM_018972) Human Un-
tagged Clone (OriGene Technologies Inc., Rockville, MD, USA) to pIRES2-AcGFP1 Vector
(TAKARA Bio, Shiga, Japan) using SacI and SalI enzymes (Thermo Fisher Scientific).
Mutagenesis for mutations in the GDAP1 gene (c.980G > A p.Gly327Asp, c.458C > T
p.Pro153Leu, c.652C > G p.Gln218Glu, c.664G > A p.Glu222Lys, c.715C > T p.Leu239Phe
and c.368A > G p.His123Arg) were performed using Mut Express II Fast Mutagenesis Kit
V2 (Vazyme Biotech Co., Ltd., Nanjing, Jiangsu, China) according to the manufacturer’s
instructions and verified by sequencing.
4.4. Protein Extracts and Western Blot Analysis
Total protein cell extracts were prepared using a cell lysis buffer (Cell Signaling Tech-
nology, Inc., Danvers, MA, USA) with 1 mM PMSF and Protease Inhibitor Cocktail 1/200
v/v (Sigma-Aldrich). Protein were separated by SDS-PAGE, transferred onto nitrocellulose
membrane Amersham Protran (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and
analyzed by standard Western blotting using rabbit polyclonal anti-GDAP1 (Abcam, Cam-
bridge, MA, USA), purified mouse anti-GM130 (BD Transduction Laboratories, San Jose,
CA, USA), rabbit polyclonal anti-B4GALT3 (Proteintech, Chicago, IL, USA), rabbit poly-
clonal anti-GORASP2 (Proteintech), rabbit anti-TGN46 (Sigma-Aldrich), mouse monoclonal
anti-beta Actin (Proteintech) antibodies and secondary anti-rabbit IgG and anti-mouse
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IgG horseradish peroxidase (HRP)-conjugated antibodies (Sigma-Aldrich) followed by
enhanced chemiluminescence (Western Bright Sirius Advansta, San Jose, CA, USA).
4.5. Drug Screening Assay
The assay was based on previously described tests [33,34]. Cells of the yeast S. cerevisiae
strain csg2∆ were grown to early exponential phase, OD600 was adjusted to 0.5, and 200 µL
was spread homogenously onto solid YPD media supplemented with 0.5 M CaCl2. Sterile
filters were placed on the media surface and 5 µL of 10 mM drug solutions in dimethyl
sulfoxide (DMSO) were applied to each filter disc. In this screen, all 1520 compounds
from the Prestwick Chemical Library (Prestwick Chemical Libraries, Illkirch-Graffenstaden,
France), 99% of which have been approved by Food and Drug Administration, USA, were
tested. DMSO was used as a vehicle control. As a positive control the csg2∆ strain with
plasmid encoding human GDAP1 gene (csg2∆ [GDAP1]) was used. The csg2∆ [GDAP1]
strain was spotted directly on the surface of the media in the corner of each plate. The
plates were incubated at 28 ◦C for 3 to 5 days. Data was recorded using a Snap Scan1212
(Agfa, Mortsel, Belgium).
4.6. Confocal Microscopy
HeLa and SH-SY5Y cells were grown on 12 mm poly-L-lysine-coated coverslips. Cells
were fixed by incubation for 15 min in 4% formaldehyde in PBS followed by 10 min of
permeabilization in 0.5% Triton-X in PBS and then blocked for 1 h in 0.1% Triton-X and 2%
BSA in PBS. The slides were incubated overnight with primary antibody: purified mouse
anti-GM130 diluted 1:40 (BD Transduction Laboratories), rabbit polyclonal anti-B4GALT3
diluted 1:65 (Proteintech), rabbit polyclonal anti-GORASP2 diluted 1:300 (Proteintech),
rabbit anti-TGN46 diluted 1:200 (Sigma-Aldrich). After washing, slides were incubated
with secondary antibody Alexa Fluor 546-conjugated goat anti-rabbit or anti-mouse IgG
(Invitrogen, Camarillo, CA, USA) diluted 1:500 for 1 h. Then slides were stained using
DAPI (Thermo Fisher Scientific) for 15 min and mounted in mounting medium (DAKO,
Agilent, Santa Clara, CA, USA).
To observe the morphology of Golgi in yeast cells, BY4741 strains carrying a SEC7-
mRFP- or SED5-mRFP- containing plasmid were transformed with empty plasmid or
plasmids bearing the indicated GDAP1 variants. Strains were grown overnight in SC-leu-
ura media at 28°C. Cultures were diluted (1:10) in fresh SC-leu-ura medium for 4 h. Cells
were collected by centrifugation, fixed by incubation for 25 min in 4% formaldehyde and
washed in KiPO4/sorbitol buffer (100 mM potassium phosphate pH 7.5 and 1.2 M sorbitol).
Fixed cultures were spotted on poly-L-lysine- or concanavalin A- coated slides and the
nucleus was stained by DAPI (Thermo Fisher Scientific) for 2 min. Slides were then washed
with water and mounted in a mounting medium (DAKO).
Cells were viewed using LSM 780 Axio Observer Z.1 confocal microscope (Zeiss,
Oberkochen, Germany). Images were collected using Zen 2012 black edition software
(Zeiss). The confocal microscopy observations were performed in the Laboratory of Ad-
vanced Microscopy Techniques, Mossakowski Medical Research Centre, PAS. At least 100
yeast cells with Sec7-mRFP and Sed5-mRFP were counted for every experimental variant.
4.7. Transmission Electron Microscopy
Cells were fixed by 2.5% glutaraldehyde, 2% paraformaldehyde (Electron Microscopy
Sciences, Hatfield, PA, USA) solution for 1 h at 4◦ C. After fixation, cells were rinsed three
times for 10 min in 0.1 M cacodylate buffer (BDH Chemicals, Dubai, UAE). Cells were then
postfixed in 2% osmium tetroxide (Agar Scientific, Stansted, United Kingdom) for 1 h at
room temperature. Dehydration was performed by incubating the sample in increasing
ethanol concentrations and then in pure propylene oxide. During dehydration, cells were
stained with 1% uranyl acetate (Serva, Heidelberg, Germany) in 70% ethanol. Finally,
cells were embedded in a mixture of propylene oxide (Electron Microscopy Sciences)
and Epon resin (Serva), then in pure Epon resin. After polymerization at 60 ◦C, 70 nm
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thick sections were collected on TEM copper grids (Ted Pella Inc., Redding, CA, USA).
Electron micrographs were obtained with Morada camera on a JEM 1400 transmission
electron microscope at 80 kV (JEOL Co., Tokyo, Japan) in the Laboratory of Electron
Microscopy Core Facility, Nencki Institute of Experimental Biology, Polish Academy of
Sciences, Warsaw, Poland.
4.8. Statistical Analysis
Statistical analyses were performed using GraphPad Prism Software (San Diego, CA,
USA) (https://www.graphpad.com/scientific-software/prism/). Student’s t-Test was
used to evaluate the statistical significance of differences between the numbers of Sec7-
mRFP puncta in transformed yeast cells. One-way ANOVA was used to evaluate the
statistical significance of differences between the fractions of cells with the indicated types
of Golgi ultrastructure. Data are presented as means ±standard deviations. The differences
are considered significant where p < 0.05.
Supplementary Materials: The following are available online at https://www.mdpi.com/1422-006
7/22/2/914/s1, Figure S1: Expression of the GDAP1 gene variants in yeast cells does not change the
localization of the cis-Golgi protein Sed5.
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J.K., D.K. (Dagmara Kabzińska); funding acquisition: A.K., K.B.; formal analysis: W.R., K.B., A.A.S.,
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